Migdal Insurance & Financial Holdings Ltd. Longboard Pharmaceuticals, Inc. Transaction History

Migdal Insurance & Financial Holdings Ltd.

$6.18 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 02, 2022	SELL	$4.0 - $6.0 $4,372 - $6,558	-1,093 Closed	0 $0
Q4 2021 Feb 02, 2022	SELL	$4.75 - $9.45 $3,135 - $6,236	-660 Reduced 37.65%	1,093 $5,000
Q3 2021 Nov 16, 2021	BUY	$8.65 - $11.36 $15,163 - $19,914	1,753 New	1,753 $16,000

Others Institutions Holding LBPH

# of Institutions

126

Shares Held

34.9M

Call Options Held

28.9K

Put Options Held

13.9K

Farallon Capital Management LLC San Francisco, CA

3.15M
Shares

$189 Million
0.53% of portfolio
Price T Rowe Associates Inc Baltimore, MD

2.91M
Shares

$174 Million
0.01% of portfolio
Cormorant Asset Management, LP Boston, MA

2.79M
Shares

$167 Million
6.52% of portfolio
Black Rock Inc. New York, NY

2.37M
Shares

$142 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

2.03M
Shares

$122 Million
0.0% of portfolio

View Full List

About Longboard Pharmaceuticals, Inc.

Ticker LBPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 13,586,000
Market Cap $815M
Description
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical ...

More about LBPH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Migdal Insurance & Financial Holdings Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Migdal Insurance & Financial Holdings Ltd. with notifications on news.

Account